Zhejiang Huahai Pharmaceutical's share price drop doesn't al...
Zhejiang Huahai Pharmaceutical's share price drop doesn't align with its EPS growth and revenue increase, hinting at other influencing factors. Last year's performance suggests unresolved issues, and long-term share price weakness could be a negative sign or a potential turnaround for contrarian investors.
Earnings Are Growing at Zhejiang Huahai Pharmaceutical (SHSE:600521) but Shareholders Still Don't Like Its Prospects
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment